Today: 30 June 2026
Browse Category

NASDAQ:RGC 4 December 2025 - 2 February 2026

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 3:41 a.m. ET — Market closed. Regencell Bioscience Holdings Limited heads into the weekend with traders focused on one thing: volatility. RGC stock finished the last regular session sharply lower, while the broader market logged weekly gains in a quiet, holiday-shortened week—setting up a potentially jumpy start to the next session when U.S. equities reopen on Monday, Dec. 29. Investopedia
28 December 2025
···
Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

NEW YORK, Dec. 27, 2025, 6:40 a.m. ET — Market closed Regencell Bioscience Holdings Limited stock heads into the weekend after a sharp Friday pullback, closing at $21.16, down 13.98% from the prior close of $24.60, in a move that put the name on multiple “top losers” radars as U.S. markets wrapped up a quiet post-Christmas session. aaii.com+2Investing.com+2
27 December 2025
·
Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

New York time check: It is Friday, December 26, 2025, 12:17 p.m. ET in New York. While the broader U.S. market is mostly drifting near record territory in subdued post‑holiday volume, Regencell Bioscience Holdings Limited is doing what it’s become famous for in 2025: moving a lot, on not much liquidity. AP News
26 December 2025
·
Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited is once again reminding markets that “biotech stock” plus “low float” can equal “physics optional.” By the close of trading on December 24, RGC finished at $24.60, down 2.57% from the prior close of $25.25, after trading between $24.60 and $26.42 on the day, with roughly 348K shares traded. StockAnalysis+1 That’s the headline tape. The deeper story—what’s making RGC such a recurring character in 2025’s “stock market does weird things” anthology—mixes extreme volatility, concentrated insider ownership, a past 38-for-1 stock split, and a disclosed U.S. Department of Justice inquiry into trading activity in the company’s shares. SEC+3Regencell Bioscience -+3SEC+3
24 December 2025
·
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited is having one of those “stock market is a strange animal” moments again: the share price is moving sharply on a story dominated less by traditional fundamentals and more by market structure—low float, extreme volatility, and ongoing legal overhang. As of Dec. 24, 2025, RGC was trading around $25.25, up roughly 14% on the day.
24 December 2025
··
Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

December 23, 2025 — Regencell Bioscience Holdings Limited is back in the spotlight on Tuesday after another sharp move higher, extending a volatile December run that’s pulled in momentum traders—and raised fresh questions about fundamentals, governance, and legal risk. As of late morning in U.S. trading, RGC was changing hands around the mid‑$23 range after opening higher, with the day’s trading range roughly $22.00–$23.99. StockAnalysis+1
23 December 2025
Regencell Bioscience (NASDAQ: RGC) Stock News Today: DOJ Probe, Extreme Volatility, and What Forecasts Say on Dec. 22, 2025

Regencell Bioscience (NASDAQ: RGC) Stock News Today: DOJ Probe, Extreme Volatility, and What Forecasts Say on Dec. 22, 2025

Regencell Bioscience Holdings Limited is back in the spotlight on Monday, Dec. 22, 2025, for the same reason it’s been impossible to ignore for most of this year: wild price swings that seem to have a complicated relationship with fundamentals. By late morning in the U.S., RGC was trading around $23 after opening near $19.43, with an intraday range of roughly $19.07 to $24.50—a very large move for a single session, even by small-cap standards. Benzinga
22 December 2025
·
Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience Holdings Limited is back on traders’ radar. On Thursday, December 4, 2025, RGC shares surged more than 20% intraday, trading in the mid‑teens after yet another volatile session in what has arguably been 2025’s most extreme stock story. Intraday data from several market trackers showed the stock changing hands around $16–17, up roughly 24–31% on the day, with the price swinging between about $13 and over $18 on volume close to 1 million shares. GuruFocus+2StockAnalysis+2 That move comes on the back of a year in which RGC has:
4 December 2025
·
1 2

Stock Market Today

  • Concentrix Q2 EPS Comes In Light, Stock Down Nearly 40% for the Year
    June 29, 2026, 7:00 PM EDT. Concentrix (CNXC) posted Q2 earnings of $2.63 a share, a penny below the Zacks Consensus of $2.64. Revenue was $2.46 billion, a 0.43% miss versus estimates, but up from $2.42 billion last year. Concentrix has only topped earnings estimates once in the past four quarters. Shares have dropped about 39.9% since the start of the year, trailing the S&P 500, which is up 7.4%. CNXC has a Zacks Rank #3 (Hold) as earnings estimate revisions remain uneven. Analysts are looking for $3.18 EPS and $2.54 billion revenue next quarter; full-year revenue is forecast at $11.65 billion. The Business-Services group sits in the top 42% of Zacks sectors. Investors are focused on the company's earnings call for any update on guidance.
Go toTop